TY - JOUR
T1 - Cardiovascular Complications of HIV in Endemic Countries
AU - Feinstein, Matthew J.
AU - Bogorodskaya, Milana
AU - Bloomfield, Gerald S.
AU - Vedanthan, Rajesh
AU - Siedner, Mark J.
AU - Kwan, Gene F.
AU - Longenecker, Christopher T.
N1 - Funding Information:
Christopher T. Longenecker reports grants from NIH (K23 HL123341). Matthew J. Feinstein reports grants from the American Heart Association (16 FTF 31200010)
Funding Information:
Christopher T. Longenecker reports personal fees from Gilead Sciences, grants from Bristol Myers-Squibb, and grants from Medtronic Philanthropy.
Publisher Copyright:
© 2016, Springer Science+Business Media New York.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Effective combination antiretroviral therapy (ART) has enabled human immunodeficiency virus (HIV) infection to evolve from a generally fatal condition to a manageable chronic disease. This transition began two decades ago in high-income countries and has more recently begun in lower income, HIV endemic countries (HIV-ECs). With this transition, there has been a concurrent shift in clinical and public health burden from AIDS-related complications and opportunistic infections to those associated with well-controlled HIV disease, including cardiovascular disease (CVD). In the current treatment era, traditional CVD risk factors and HIV-related factors both contribute to an elevated risk of myocardial infarction, stroke, heart failure, and arrhythmias. In HIV-ECs, the high prevalence of persons living with HIV and growing prevalence of CVD risk factors will contribute to a growing epidemic of HIV-associated CVD. In this review, we discuss the epidemiology and pathophysiology of cardiovascular complications of HIV and the resultant implications for public health efforts in HIV-ECs.
AB - Effective combination antiretroviral therapy (ART) has enabled human immunodeficiency virus (HIV) infection to evolve from a generally fatal condition to a manageable chronic disease. This transition began two decades ago in high-income countries and has more recently begun in lower income, HIV endemic countries (HIV-ECs). With this transition, there has been a concurrent shift in clinical and public health burden from AIDS-related complications and opportunistic infections to those associated with well-controlled HIV disease, including cardiovascular disease (CVD). In the current treatment era, traditional CVD risk factors and HIV-related factors both contribute to an elevated risk of myocardial infarction, stroke, heart failure, and arrhythmias. In HIV-ECs, the high prevalence of persons living with HIV and growing prevalence of CVD risk factors will contribute to a growing epidemic of HIV-associated CVD. In this review, we discuss the epidemiology and pathophysiology of cardiovascular complications of HIV and the resultant implications for public health efforts in HIV-ECs.
KW - Cardiovascular epidemiology
KW - Global health
KW - HIV
KW - Health disparities
KW - Human immunodeficiency virus
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=84991113200&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991113200&partnerID=8YFLogxK
U2 - 10.1007/s11886-016-0794-x
DO - 10.1007/s11886-016-0794-x
M3 - Review article
C2 - 27730474
AN - SCOPUS:84991113200
VL - 18
JO - Current Cardiology Reports
JF - Current Cardiology Reports
SN - 1523-3782
IS - 11
M1 - 113
ER -
